Maytansine
Research stageAlso known as Maitansine.
Recent clinical, regulatory, research and industry developments relating to this drug.
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers.
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Annals of oncology : official journal of the European Society for Medical Oncology1
- Cancer research1
- Gynecologic oncology1
- International journal of gynecological cancer : official journal of the International Gynecological Cancer Society1
- International journal of molecular sciences1
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
- Chari RV2
- Coleman RL2
- Lambert JM2
- Oaknin A2
- Anton A1
- Arce-Salinas C1
- Armetta J1
- Ashfaque S1
- Aichi Cancer Center Hospital1
- Asan Medical Center1
- Bon Secours Hospital and Clinical Trials1
- Breast Center1
- Centre Leon Berard1
- Centre Léon Bérard1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 5 of the same disease areas as Maytansine in the shared literature.
Studied across 4 of the same disease areas as Maytansine in the shared literature.
Studied across 3 of the same disease areas as Maytansine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature